MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-509-0444
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$360,000.00
Profitability
Miscellaneous
Employees12
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
MYOS (NASDAQ:MYOS) Frequently Asked Questions
What is MYOS's stock symbol?
MYOS trades on the NASDAQ under the ticker symbol "MYOS."
How were MYOS's earnings last quarter?
MYOS Co. (NASDAQ:MYOS) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The business earned $0.15 million during the quarter, compared to the consensus estimate of $0.14 million. MYOS had a negative return on equity of 93.90% and a negative net margin of 603.47%. View MYOS's Earnings History.
When is MYOS's next earnings date?
Has MYOS been receiving favorable news coverage?
Media stories about MYOS stock have been trending negative on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. MYOS earned a news impact score of -2.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for MYOS.
Are investors shorting MYOS?
MYOS saw a decline in short interest in August. As of August 31st, there was short interest totalling 91,100 shares, a decline of 10.4% from the July 31st total of 101,700 shares. Based on an average daily volume of 25,500 shares, the short-interest ratio is presently 3.6 days. Approximately 1.8% of the company's stock are sold short. View MYOS's Current Options Chain.
Who are some of MYOS's key competitors?
Some companies that are related to MYOS include Moleculin Biotech (MBRX), Proteostasis Therapeutics (PTI), Oramed Pharmaceuticals (ORMP), Hoth Therapeutics (HOTH), CTI BioPharma (CTIC), Morphic (MORF), Medicure (MCUJF), IVERIC bio (ISEE), Adamis Pharmaceuticals (ADMP), SUMMIT THERAPEU/S (SMMT), PLx Pharma (PLXP), Vistagen Therapeutics (VTGN), Pharmaxis (PXSLY), Vascular Biogenics (VBLT) and VIVUS (VVUS).
What other stocks do shareholders of MYOS own?
Who are MYOS's key executives?
MYOS's management team includes the folowing people:
- Mr. Joseph Mannello, CEO & Director (Age 61)
- Mr. Ren Ren, Global Chairman (Age 57)
- Mr. Joseph DiPietro, Controller
- Mr. Magshoud Dariani, Chief Technology Officer
- Mr. Kris Ohrenick, Head of Marketing
Who are MYOS's major shareholders?
MYOS's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Community Capital Management Inc. (1.55%). Company insiders that own MYOS stock include Christopher Pechock and Joseph Mannello. View Institutional Ownership Trends for MYOS.
Which major investors are buying MYOS stock?
MYOS stock was acquired by a variety of institutional investors in the last quarter, including Community Capital Management Inc.. Company insiders that have bought MYOS stock in the last two years include Christopher Pechock and Joseph Mannello. View Insider Buying and Selling for MYOS.
How do I buy shares of MYOS?
Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MYOS's stock price today?
One share of MYOS stock can currently be purchased for approximately $1.56.
How big of a company is MYOS?
MYOS has a market capitalization of $14.31 million and generates $360,000.00 in revenue each year. The company earns $-3,220,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. MYOS employs 12 workers across the globe.View Additional Information About MYOS.
What is MYOS's official website?
How can I contact MYOS?
MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]
MarketBeat Community Rating for MYOS (NASDAQ MYOS)
MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
